Barings LLC Makes New Investment in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Barings LLC bought a new position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,933 shares of the company’s stock, valued at approximately $173,000.

Several other hedge funds also recently bought and sold shares of RDY. Farther Finance Advisors LLC increased its position in Dr. Reddy’s Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after purchasing an additional 137 shares during the last quarter. Van ECK Associates Corp increased its position in Dr. Reddy’s Laboratories by 64.3% in the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after purchasing an additional 322 shares during the last quarter. QRG Capital Management Inc. increased its position in Dr. Reddy’s Laboratories by 19.5% in the 3rd quarter. QRG Capital Management Inc. now owns 9,454 shares of the company’s stock worth $751,000 after purchasing an additional 1,544 shares during the last quarter. AIA Group Ltd increased its position in Dr. Reddy’s Laboratories by 9.6% in the 3rd quarter. AIA Group Ltd now owns 26,793 shares of the company’s stock worth $2,129,000 after purchasing an additional 2,354 shares during the last quarter. Finally, Assetmark Inc. increased its position in Dr. Reddy’s Laboratories by 8.1% in the 3rd quarter. Assetmark Inc. now owns 37,666 shares of the company’s stock worth $2,993,000 after purchasing an additional 2,836 shares during the last quarter. 3.85% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th.

Dr. Reddy’s Laboratories Stock Performance

RDY opened at $12.93 on Friday. The company has a market cap of $10.79 billion, a PE ratio of 20.59 and a beta of 0.48. The stock has a 50-day moving average of $14.18 and a 200-day moving average of $14.94. Dr. Reddy’s Laboratories Limited has a 52-week low of $12.62 and a 52-week high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities research analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.